Beam Therapeutics (BEAM) announced that the FDA has cleared the investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency. AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there are no currently approved curative treatments.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics today
- Promising Data and Future Potential Drive Buy Rating for Beam Therapeutics
- Cathie Wood Buys the Dip in Baidu Stock (BIDU) and Sells Roblox
- Strategic Advantage and Exclusive Rights Bolster Beam Therapeutics’ Buy Rating
- Beam, Unity, Checkpoint, Inuvo, Ocular: Trending by Analysts